Lv38
260 积分 2026-01-19 加入
The Lasting Impact of IL-2: Approaching 50 Years of Advancing Immune Tolerance, Cancer Immunotherapies, and Autoimmune Diseases
4小时前
待确认
Treatment of idiopathic pulmonary fibrosis: an update on emerging drugs in phase II & III clinical trials
3天前
已完结
Commonalities Between pDCs and B Cells
5天前
已关闭
Inhaled Treprostinil for Idiopathic Pulmonary Fibrosis
13天前
已完结
Positive results for obinutuzumab in SLE phase III trial
14天前
已完结
Rozanolixizumab in generalized myasthenia gravis: Pooled analysis of the Phase 3 MycarinG study and two open-label extensions
17天前
已完结
Obexelimab in Systemic Lupus Erythematosus With Exploration of Response Based on Gene Pathway Co‐Expression Patterns: A Double‐Blind, Randomized, Placebo‐Controlled, Phase 2 Trial
17天前
已完结
Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial
17天前
已完结
A Phase 3 Trial of Inebilizumab in Generalized Myasthenia Gravis
17天前
已完结
Discovery of GS-2278, a Potent and Selective LPAR1 Antagonist for the Treatment of Idiopathic Pulmonary Fibrosis
20天前
已完结
皖公网安备34019202002308
